Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Background Adalimumab is a fully human, monoclonal antibody against tumor necrosis factor that is approved in Western countries for the treatment of moderately to severely active ulcerative colitis (UC).